{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:12:47Z","timestamp":1793895167835,"version":"4.8.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jacc.2025.08.054","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T06:42:08Z","timestamp":1756536128000},"page":"2513-2526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction"],"prefix":"10.1016","volume":"86","author":[{"given":"Bart J.","family":"van Essen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan C.H.","family":"Ceelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2000-9358","authenticated-orcid":false,"given":"Wouter","family":"Ouwerkerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiew-Hwa K.","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganash N.","family":"Tharshana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fook Ming","family":"Hew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ezekowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Tromp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jacc.2025.08.054_bib1","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/ejhf.1585","article-title":"Heart failure around the world","volume":"21","author":"Tromp","year":"2019","journal-title":"Eur J Heart Fail."},{"issue":"36","key":"10.1016\/j.jacc.2025.08.054_bib2","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.jacc.2025.08.054_bib3","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.jacc.2025.08.054_bib4","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.jacc.2025.08.054_bib5","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.jacc.2025.08.054_bib6","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jacc.2025.08.054_bib7","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jacc.2025.08.054_bib8","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients withworsening chronic heart failure and reduced ejection fraction the socrates-reduced randomized trial","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jacc.2025.08.054_bib9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacc.2025.08.054_bib10","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s10557-020-07099-2","article-title":"Relative Efficacy of sacubitril-valsartan, vericiguat, and SGLT2 Inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis","volume":"35","author":"Aimo","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"issue":"9","key":"10.1016\/j.jacc.2025.08.054_bib11","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1234","article-title":"Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"20","author":"Komajda","year":"2018","journal-title":"Eur J Heart Fail."},{"issue":"1","key":"10.1016\/j.jacc.2025.08.054_bib12","doi-asserted-by":"crossref","first-page":"e003529","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529","article-title":"Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"10","author":"Burnett","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.jacc.2025.08.054_bib13","doi-asserted-by":"crossref","first-page":"e002364","DOI":"10.1136\/openhrt-2023-002364","article-title":"Comparative cardiovascular outcomes of novel drugs as an addition to conventional triple therapy for heart failure with reduced ejection fraction (HFrEF): a network meta-analysis of randomised controlled trials","volume":"10","author":"Suebsaicharoen","year":"2023","journal-title":"Open Heart"},{"issue":"1","key":"10.1016\/j.jacc.2025.08.054_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-024-04339-3","article-title":"The most effective combination of pharmacological therapy for heart failure with reduced ejection fraction: a network meta-analysis of randomized controlled trials","volume":"24","author":"Tang","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"10.1016\/j.jacc.2025.08.054_bib15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/joim.13487","article-title":"Network meta-analysis of medical therapy efficacy in more than 90,000 patients with heart failure and reduced ejection fraction","volume":"292","author":"De Marzo","year":"2022","journal-title":"J Intern Med"},{"issue":"2","key":"10.1016\/j.jacc.2025.08.054_bib16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail."},{"issue":"11","key":"10.1016\/j.jacc.2025.08.054_bib17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"10510","key":"10.1016\/j.jacc.2025.08.054_bib18","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(25)01665-4","article-title":"Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"406","author":"Butler","year":"2025","journal-title":"Lancet"},{"issue":"29","key":"10.1016\/j.jacc.2025.08.054_bib19","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1002\/sim.5453","article-title":"Quantifying the impact of between-study heterogeneity in multivariate meta-analyses","volume":"31","author":"Jackson","year":"2012","journal-title":"Stat Med"},{"key":"10.1016\/j.jacc.2025.08.054_bib20","series-title":"An Introduction to meta-analysis with R","first-page":"3","author":"Schwarzer","year":"2015"},{"issue":"4","key":"10.1016\/j.jacc.2025.08.054_bib21","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Res Synth Methods"},{"issue":"25","key":"10.1016\/j.jacc.2025.08.054_bib22","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1002\/sim.6236","article-title":"Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis","volume":"33","author":"R\u00fccker","year":"2014","journal-title":"Stat Med"},{"issue":"16","key":"10.1016\/j.jacc.2025.08.054_bib23","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.105.582320","article-title":"Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III","volume":"112","author":"Willenheimer","year":"2005","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacc.2025.08.054_bib24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Syst Rev."},{"issue":"1","key":"10.1016\/j.jacc.2025.08.054_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"10.1016\/j.jacc.2025.08.054_bib26","doi-asserted-by":"crossref","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"Cinema: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacc.2025.08.054_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jclinepi.2021.07.011","article-title":"GRADE guidelines 33: addressing imprecision in a network meta-analysis","volume":"139","author":"Brignardello-Petersen","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.jacc.2025.08.054_bib28","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/ejhf.531","article-title":"A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF","volume":"18","author":"Voors","year":"2016","journal-title":"Eur J Heart Fail."},{"issue":"8","key":"10.1016\/j.jacc.2025.08.054_bib29","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/eurjhf\/hft045","article-title":"Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry","volume":"15","author":"Lam","year":"2013","journal-title":"Eur J Heart Fail."},{"issue":"23","key":"10.1016\/j.jacc.2025.08.054_bib30","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMc1509753","article-title":"Estimating the long-term treatment benefits of sacubitril\u2013valsartan","volume":"373","author":"Claggett","year":"2015","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jacc.2025.08.054_bib31","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jacc.2025.08.054_bib32","first-page":"e16332","article-title":"Comparison of sacubitril\/valsartan versus enalapril in the management of heart failure","volume":"13","author":"Bano","year":"2021","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.jacc.2025.08.054_bib33","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00228-022-03290-6","article-title":"Clinical comparative study assessing the effect of ivabradine on neopterin and NT-Pro BNP against standard treatment in chronic heart failure patients","volume":"78","author":"Dogheim","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.jacc.2025.08.054_bib34","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1002\/ejhf.2355","article-title":"A randomized clinical trial on the short-term effects of 12-week sacubitril\/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the ACTIVITY-HF study","volume":"23","author":"Halle","year":"2021","journal-title":"Eur J Heart Fail."},{"issue":"3","key":"10.1016\/j.jacc.2025.08.054_bib35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/jama.2022.11016","article-title":"Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction: the METEORIC-HF randomized clinical trial","volume":"328","author":"Lewis","year":"2022","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.jacc.2025.08.054_bib36","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.12998\/wjcc.v12.i18.3468","article-title":"Effect of dapagliflozin on uric acid in patients with chronic heart failure and hyperuricemia","volume":"12","author":"Lin","year":"2024","journal-title":"World J Clin Cases"},{"issue":"1","key":"10.1016\/j.jacc.2025.08.054_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of treatment with sacubitril\/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"7","author":"Mann","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"10","key":"10.1016\/j.jacc.2025.08.054_bib38","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/ejhf.2560","article-title":"Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial","volume":"24","author":"Palau","year":"2022","journal-title":"Eur J Heart Fail."},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2025.08.054_bib39","article-title":"Effects of dapagliflozin on myocardial performance in non-diabetic patients with heart failure with reduced and mid-range ejection fraction (DAPA ECHO trial)","volume":"45","author":"Pastore","year":"2024","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.jacc.2025.08.054_bib40","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.3390\/jcm11102935","article-title":"Dapagliflozin impact on the exercise capacity of non-diabetic heart failure with reduced ejection fraction patients","volume":"11","author":"Reis","year":"2022","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.jacc.2025.08.054_bib41","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.054_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2021.05.005","article-title":"Sacubitril\/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: a randomized, double-blind, active-controlled study","volume":"239","author":"dos Santos MR","year":"2021","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.jacc.2025.08.054_bib43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jjcc.2016.11.011","article-title":"Efficacy and safety of sacubitril\/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: rationale for and design of the randomized, double-blind PARALLEL-HF study","volume":"70","author":"Tsutsui","year":"2017","journal-title":"J Cardiol"},{"issue":"6","key":"10.1016\/j.jacc.2025.08.054_bib44","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jacc.2022.05.027","article-title":"Sustained-release ivabradine hemisulfate in patients with systolic heart failure","volume":"80","author":"Ye","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacc.2025.08.054_bib45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)\u2014a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail."},{"issue":"37","key":"10.1016\/j.jacc.2025.08.054_bib46","doi-asserted-by":"crossref","first-page":"62693","DOI":"10.18632\/oncotarget.18570","article-title":"Effects of liraglutide on hemodynamic parameters in patients with heart failure","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.jacc.2025.08.054_bib47","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"issue":"10510","key":"10.1016\/j.jacc.2025.08.054_bib48","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(25)01682-4","article-title":"Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials","volume":"406","author":"Zannad","year":"2025","journal-title":"Lancet"},{"issue":"10244","key":"10.1016\/j.jacc.2025.08.054_bib49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725075722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725075722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T21:05:10Z","timestamp":1769202310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725075722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":49,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0735109725075722"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.08.054","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.08.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}